Latest Health News

BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.

US Masters Residential Property Group has announced a special distribution of 10 cents per stapled security, payable in early August 2025. Investors should note key dates for eligibility and payment.

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.

Holista Colltech has confirmed Leong Man Loong as its permanent CEO, cementing leadership stability during a pivotal recovery phase. His symbolic $1 salary underscores a commitment to long-term growth.

NT Minerals has agreed to sell its Redbank and Wollogorang copper projects to Golden Horse Minerals for $3 million in combined cash and equity, shifting its strategic focus to other critical mineral assets.

Keybridge Capital has obtained a $9.3 million bridge funding facility from Active Asset Management, supported by an ASX waiver allowing the deal without prior shareholder approval. The funding aims to address urgent liquidity and solvency challenges while trading remains suspended.

Vitasora Health has secured approximately A$11 million in capital to accelerate its expansion in the US remote patient monitoring market, highlighted by an upgraded contract with TPAC covering 15,000 patients. The company targets a USD 18 million annual recurring revenue run-rate by late 2026.

Vitasora Health Limited has raised $11 million in a well-supported placement, positioning the company to achieve cash flow breakeven in the second half of FY2026. The capital injection underscores strong investor confidence following key contract expansions and operational milestones.

Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.

Findi Limited will have its trading suspension lifted on 2 July 2025 following the lodgement of its 2025 annual report, reopening its shares to market activity.

The Reject Shop Limited has received Federal Court approval for its Scheme, enabling a fully franked special dividend of AUD 0.77 per share payable mid-July.

Eildon Capital Group has revealed a significant loan repayment default by Kings Investment, alongside a cautious outlook for its FY25 financials amid a sluggish Melbourne property market.